Ultragenyx Pharmaceutical Inc
RARE
ISIN US90400D1081 / Valor 22860122
Ultragenyx Pharmaceutical Inc
UMushroom community rating:
About company
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for rare and ultra-rare genetic diseases. The company's portfolio includes products such as DOJOLVI® for long-chain fatty acid oxidation disorders and CRYSVITA® for X-linked hypophosphatemia and tumor-induced osteomalacia. Ultragenyx is dedicated to providing patients with life-changing therapies that address unmet medical needs in the rare disease community.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.08.2024):
Total Revenues
Ultragenyx Pharmaceutical Inc. reported $109 million in total revenue for the first quarter of 2024, which represents an 8% growth compared to the same period in 2023.
Operating Expenses
Total operating expenses for the first quarter of 2024 were $274 million, including non-cash stock-based compensation of $37 million.
Net Loss
For the first quarter of 2024, Ultragenyx Pharmaceutical Inc. reported a net loss of $171 million, or $2.03 per share basic and diluted, compared with a net loss for the first quarter of 2023 of $164 million, or $2.33 per share, basic and diluted.
Net Cash Used in Operations and Cash Balance
Net cash used in operations for the quarter ended March 31, 2024, was $191 million.
2024 Financial Guidance
For the full year 2024, Ultragenyx Pharmaceutical Inc. reaffirms its total revenue guidance in the range of $500 million to $530 million, with Crysvita revenue expected to be between $375 million to $400 million and Dojolvi revenue between $75 million to $80 million.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
4043 M
Market cap (USD)
401,172
Daily traded volume (Shares)
45.15 / 43.39
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
